A novel adenovirus expressing human 4–1BB ligand enhances antitumor immunity

Yoshida, Hiroshi; Katayose, Yu; Unno, Michiaki; Suzuki, Masanori; Kodama, Hideaki; Takemura, Shinichi; Asano, Ryutaro; Hayashi, Hiroki; Yamamoto, Kuniharu; Matsuno, Seiki; Kudo, Tetsuichi

doi:10.1007/s00262-002-0334-y

Cited by 22 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to CIK cells originate from the venous blood of sick patients or fitness people, it is relatively easy to culture and expand. At present, CIK cells are widely used in adjuvant treatment of tumors ( 85 ). According to this, a great number of clinical experiments were carried out to treat lots of tumors, such as kidney cancer Hodgkin’s lymphoma, leukemia and liver cancer.…”

Section: Cell Therapymentioning

confidence: 99%

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

et al. 2023

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a highly malignant tumor of the hepatobiliary system that has failed to respond to many traditional therapies to a certain extent, including surgery, chemotherapy and radiotherapy. In recent years, the new therapeutic schemes based on immunology have fundamentally changed the systemic treatment of various malignant tumors to a certain extent. In view of the immunogenicity of CCA, during the occurrence and development of CCA, some immunosuppressive substances are released from cells and immunosuppressive microenvironment is formed to promote the escape immune response of its own cells, thus enhancing the malignancy of the tumor and reducing the sensitivity of the tumor to drugs. Some immunotherapy regimens for cholangiocarcinoma have produced good clinical effects. Immunotherapy has more precise characteristics and less adverse reactions compared with traditional treatment approaches. However, due to the unique immune characteristics of CCA, some patients with CCA may not benefit in the long term or not benefit at all after current immunotherapy. At present, the immunotherapy of CCA that have been clinically studied mainly include molecular therapy and cell therapy. In this article, we generalized and summarized the current status of immunotherapy strategies including molecular therapy and cell therapy in CCA in clinical studies, and we outlined our understanding of how to enhance the clinical application of these immunotherapy strategies.

show abstract

Section: Cell Therapymentioning

confidence: 99%

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The results of several other studies have also indicated that bispecific antibodies provide satisfactory effects and have a wide range of applications ( 38 , 39 ). In 2003, a study reported that an anti-mucin 1/anti-CD3 bispecific antibody indirectly increased the antitumor activity of a 4-1BB ligand-encoding adenovirus in CCA ( 40 ). However, no other findings about bispecific antibodies in CCA have yet been reported.…”

Section: Immunotherapymentioning

confidence: 99%

Latest evidence on immunotherapy for cholangiocarcinoma (Review)

Guo

Shen

2020

Oncol Lett

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a type of aggressive tumor that involves the intrahepatic, perihilar and distal biliary tree, and is usually diagnosed at an advanced stage. The standard first-line systemic therapy for patients with advanced CCA is a combination of gemcitabine and cisplatin; targeted therapies and angiogenesis inhibitors are not widely used clinically at present. However, with the development of precision medicine, immunotherapy has started to play a more important role. Programmed cell death protein 1 inhibitors are now considered a good therapeutic option for CCA. Treatments using chimeric antigen receptor T cells, bispecific antibodies, oncolytic viruses and cancer vaccines have also achieved satisfactory results. In addition, combinations of immunotherapy with a variety of conventional therapies have shown some efficacy, and several studies have provided insights into their use in antitumor therapy. Although there are numerous challenges in the treatment of advanced CCA, immunotherapy remains a noteworthy breakthrough. The current evidence on the immunotherapy of CCA is discussed in the present review.

show abstract

“…The targeting of 4-1BB or its ligand (4-1BBL), a member of the tumor necrosis factor superfamily, may have the potential to induce antitumor immune T-cell responses. A replication-deficient adenoviral vector construct carrying 4-1BBL caused significant tumor growth inhibition in cholangiocarcinoma bearing mice [52]. Likewise, the coadministration of 2 different adenoviral vector constructs carrying either IL-12 or 4-1BBL yielded a significant antitumor T-cell response and prolonged the survival time in a mouse model bearing colon cancer (MCA26 cells) [53].…”

Section: Immune Cytokines As Immune Gene Therapy Toolsmentioning

confidence: 99%

Immune gene therapy of cancer

Akbulut

2020

Turk J Med Sci

View full text Add to dashboard Cite

Cancer gene therapy emerged as a promising treatment modality 3 decades ago. However, the failure of the first gene therapy trials in cancer treatment has decreased its popularity. Likewise, immunotherapy has followed a similar course. While it was a popular and promising treatment with IL-2 and interferon and cancer vaccines in the 1980s, it later lost its popularity. Immunotherapy became one of the main options for cancer treatment with the successful use of immune checkpoint inhibitors in clinics approximately 10 years ago. The success of immunotherapy has increased even more with the introduction of cancer gene therapy methods in this area. With the identification of the oncolytic herpes simplex virus and Chimeric antigen receptor (CAR) T-cells, immune gene therapy has become an essential modality in cancer treatments such as surgery, radiotherapy, chemotherapy, and targeted therapies.

show abstract

A novel adenovirus expressing human 4–1BB ligand enhances antitumor immunity

Cited by 22 publications

References 29 publications

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

Latest evidence on immunotherapy for cholangiocarcinoma (Review)

Immune gene therapy of cancer

Contact Info

Product

Resources

About